KEYMED BIO-B(02162.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 1.22 billion, turned profitable from a loss YoY

NewTimeSpace News: August 19, 2026, KEYMED BIO-B(02162.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 617.07 million, increased by 23.72% YoY; Net Profit stood at CNY 1.22 billion, turned profitable from a loss YoY; Profit Attributable to Shareholders stood at CNY 1.22 billion, turned profitable from a loss YoY; Basic Earnings Per Share (EPS) stood at CNY 4.29.

In terms of profitability, KEYMED BIO-B Gross Profit changed from CNY 465.28 million in the same period last year to CNY 498.33 million in the current period, increased by CNY 33.05 million; gross profit margin changed from 93.29% in the same period last year to 80.76% in the current period, decreased by 12.53 percentage points; net profit changed from loss of CNY 78.8 million in the same period last year to CNY 1.22 billion in the current period, increased by CNY 1.3 billion; net profit margin changed from -15.8% in the same period last year to 197.32% in the current period, increased by 213.12 percentage points. 

In terms of earnings quality, KEYMED BIO-B Operating Profit changed from loss of CNY 67.64 million in the same period last year to CNY 1.51 billion in the current period, increased by CNY 1.58 billion; Operating Profit Margin changed from -13.56% in the same period last year to 245.44% in the current period, increased by 259 percentage points. 

In terms of financial soundness, KEYMED BIO-B Debt-to-Asset Ratio changed from 31% in the same period last year to 29.33% in the current period, decreased by 1.67 percentage points; Total Equity changed from CNY 3.195 billion in the same period last year to CNY 4.007 billion in the current period, increased by CNY 811.21 million; Current Liabilities changed from CNY 805.34 million in the same period last year to CNY 816.55 million in the current period, increased by CNY 11.22 million; Quick Ratio changed from 3.74 in the same period last year to 4.55 in the current period, increased by 0.81 percentage points. 

In terms of R&D investment focus, KEYMED BIO-B R&D Expenses changed from CNY 360.02 million in the same period last year to CNY 338.75 million in the current period, decreased by CNY 21.27 million; R&D to Total Revenue Ratio changed from 72.18% in the same period last year to 54.9% in the current period, decreased by 17.28 percentage points. 

NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.